{"id":"NCT02603107","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","officialTitle":"A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-20","primaryCompletion":"2017-05-15","completion":"2019-12-23","firstPosted":"2015-11-11","resultsPosted":"2018-06-06","lastUpdate":"2020-12-29"},"enrollment":578,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"RTV","otherNames":[]},{"type":"DRUG","name":"ATV","otherNames":[]},{"type":"DRUG","name":"DRV","otherNames":[]},{"type":"DRUG","name":"COBI","otherNames":["Tybost®","GS-9350"]},{"type":"DRUG","name":"ATV/co","otherNames":["Evotaz®"]},{"type":"DRUG","name":"DRV/co","otherNames":["Prezcobix®"]},{"type":"DRUG","name":"FTC/TDF","otherNames":["Truvada®"]},{"type":"DRUG","name":"ABC/3TC","otherNames":[]},{"type":"DRUG","name":"B/F/TAF","otherNames":["Biktarvy®"]}],"arms":[{"label":"B/F/TAF","type":"EXPERIMENTAL"},{"label":"Stay on Baseline Regimen (SBR)","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of boosted atazanavir (ATV) or darunavir (DRV) plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) in HIV-1 infected adults who are virologically suppressed.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"B/F/TAF","deltaMin":1.7,"sd":null},{"arm":"Stay on Baseline Regimen (SBR)","deltaMin":1.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"1.00"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":119,"countries":["United States","Australia","Belgium","Canada","Dominican Republic","France","Germany","Italy","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["29925490","31430369","36912172"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":290},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Diarrhoea","Back pain"]}}